



2020 Annual Report

Dear Stockholders,

This is my first of hopefully many letters to come. As the President and CEO of CareDx, I am honored to be leading this remarkable company. CareDx has invested in building a strong foundation over the last two decades by being a leading innovator and partner in the transplant ecosystem. We plan to continue driving this incredible mission to improve outcomes for transplant patients.

In 2020, the entire world was stopped in its tracks by the COVID-19 pandemic. As the world's largest publicly traded company dedicated to transplantation, we at CareDx recognized our obligation to our patients during this time of change and chaos. By focusing on patients, we provided new ways to monitor transplant health despite the unprecedented challenges of the pandemic and built a sustainable path to provide best-in-class services to every patient.

I would like to share three new ways in which CareDx further accelerated its strategy to be the leading partner in the transplant patient journey during 2020.

The first is with our support of the patient. Within a week of the onset of the March 2020 shutdowns due to COVID, we were able to build and launch an offering called RemoTraC, a mobile phlebotomy solution for transplant patients, which today is used by patients associated with more than 150 transplant centers. This implementation excellence was only possible because of the long-standing relationship and trust we had already established with centers given our singular focus on all things transplant. We have since furthered our relationship with the patient by offering a transplant-specific smartphone app called AlloCare. By adding RemoTraC and AlloCare to the existing patient-centric approach of our patients care managers, we can now assist more patients through their transplant journey from access to testing without safety or transportation concerns, day-to-day medication compliance tracking and appointment reminders.

The second is continuing to lead with innovation as we received the first multi-modality approval through MoIDx, with the recent approval of HeartCare. This continues our tradition of being a leader in transplant. We were the first in transplant to have gene-expression profiling technology approved for use, and the first to bring donor-derived cell free DNA to the clinic. Now, we are the first to bring multi-modality as a unified offering, to increase clinical utility. We are proud to have helped bring innovation and continue to elevate the focus around the field of transplant.

The third is with the rapid progression of our rich program pipeline into new areas. In 2020, we continued to broaden our portfolio across the transplant continuum. We submitted AlloSure Lung to MoIDx for reimbursement approval. We also started our new cell therapy and stem cell business with AlloCell and AlloSeq HCT. With our strong pipeline, we expect to deliver new clinical solutions for solid organ, stem cell and cell therapy transplant patients for years to come.

I am proud of the entire CareDx team. Despite the pandemic, this team delivered outstanding results in 2020, expanded the portfolio, improved our connection with patients, and acted as a leader should by putting patients first with our decision-making.

We have both a tremendous opportunity and responsibility at CareDx to continue to improve transplant patient outcomes. I am energized by our mission every day and look forward to this challenge in the years to come as we continue on this gratifying journey.

Warm regards,



Dr. Reg Seeto

President and CEO

CORPORATE INFORMATION

Board of Director

Peter Maag, PhD
Executive Chair of the Board
CareDx, Inc.

Michael D. Goldberg, MBA
Lead Independent Director
Audit Committee
Compensation Committee,
Nominating/Corporate Governance

Fred E. Cohen, MD, DPhil
Senior Managing Director
Vida Ventures
Compensation Committee*,
Science and Technology Committee

Grace Colón, PhD
President & CEO Incarda Therapeutics, Inc.
Compensation Committee,
Science and Technology Committee*

Chris M. Cournoyer
Audit Committee,
Science and Technology Committee

Reginald Seeto, MBBS
President and Chief Executive Officer
CareDx, Inc.

Ralph Snyderman, MD
Chancellor Emeritus & James B. Duke
Professor of Medicine
Duke University
Nominating/Corporate Governance
Committee*,
Science and Technology Committee

George W. Bickerstaff, III
Managing Director
MM Dillon & Co.
Audit Committee*

William Hagstrom
CEO, Octave Bioscience
Audit Committee,
Compensation Committee

*Indicates Chairperson of the Committee

Executive Team

Reginald Seeto, MBBS
President and Chief Executive Officer

Ankur Dhingra
Chief Financial Officer

Sasha King
Chief Marketing Officer

Annual Stockholders Meeting

June 15, 2021 at 10AM PST
Virtual Meeting via live webcast at:
<http://www.virtualshareholdermeeting.com/CDNA2021>

Exchange

Nasdaq Global Market

Ticker Symbol CDNA

Transfer Agent

Computershare Trust Company, N.A.
PO Box 30170
College Station, TX 77842

Legal Counsel

Paul Hastings LLP
1117 S. California Avenue
Palo Alto, CA 94034

Independent Registered Public Accounting Firm

Deloitte
225 West Santa Clara Street, Suite 600
San Jose, CA 95113

Investor Relations

Gilmartin Group
1628 Tiburon Blvd
Belvedere Tiburon, CA 94902

Note on Forward-Looking Statements

This annual report contains forward-looking statements within the meaning of the federal securities laws. Results could differ materially. Further information on factors that could affect results is included in the 2020 Form 10- included in this annual report.

CareDx, Inc

1 Tower Place, 9th Floor
South San Francisco, CA 94080
Tel 415.287.2300
Fax 415.287.2450
WWW.CAREDX.COM

